CASC3 and neoplasm: Previous studies indicated that mutations [32] and changes in expression levels [33] of proteasome subunits, UPR signaling pathways [34], activation of autophagy [35], and even inhibition of apoptosis [36] could lead to tumor cell resistance to BTZ.